Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q16877
UPID:
F264_HUMAN
Alternative names:
6PF-2-K/Fru-2,6-P2ase testis-type isozyme
Alternative UPACC:
Q16877; Q5S3G5; Q5XLC2; Q64EX5
Background:
The 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4, also known as 6PF-2-K/Fru-2,6-P2ase testis-type isozyme, plays a pivotal role in the synthesis and degradation of fructose 2,6-bisphosphate. This enzyme is crucial for regulating glycolysis and gluconeogenesis, processes essential for energy production and glucose metabolism in cells.
Therapeutic significance:
Understanding the role of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 could open doors to potential therapeutic strategies. Its critical function in energy metabolism pathways highlights its potential as a target for metabolic disorder treatments.